GILD's recent upbeat data on lenacapavir underscore the investigational drug???s potential to prevent HIV in the targeted ...

Despite major advances in scientific innovation, access to care and growth of health systems, there are still millions of ...

Lenacapavir is a long-acting injectable drug that has proven 100 per cent successful in clinical tests and subsequent human ...

Gilead Sciences, Inc. (Nasdaq: GILD) today announced the upcoming presentation of new findings from its antiviral research ...

Gilead Sciences’s decision to distribute HIV prevention drug lenacapavir made the news this month when they signed ...

Analyst Michael Yee from Jefferies maintained a Buy rating on Gilead Sciences (GILD – Research Report) and keeping the price target at ...

The second of two pivotal studies of a six-monthly HIV prevention injection containing the antiretroviral drug lenacapavir ...

In June, we heard what could be this year's biggest HIV breakthrough: a twice-yearly injection can prevent HIV infection. Findings from a second large study of the jab has now confirmed that it works.

Gilead Sciences has taken a major step towards increasing global access to HIV prevention with the signing of royalty-free voluntary licensing agreements with six generic manufacturers ...

The report, commissioned and funded by Gilead, offers a roadmap that could help countries achieve the United Nations' goal of eliminating HIV by 2030. It also maintains that the tools are ...

Gilead Sciences’ already dominant position in HIV pre-exposure prophylaxis (PrEP) has been consolidated by a new study showing that its twice-yearly injectable drug was 100% effective in ...

Virology Therapeutic Area Head at Gilead Sciences. “The data reflect our unwavering commitment to advance scientific innovations in virology, aimed at addressing urgent global needs.” HIV ...